Q-omics provides the consensus-scored C3orf18 profile across patient tissues and cancer cell-line models. C3orf18 expression is associated with patient survival in 24 of 34 cancer types, with the highest sampling consensus in KIRP. Among the 18 cancer types available for tumor–normal comparison, C3orf18 is differentially expressed in 16, with the highest sampling consensus in KIRC. Additionally, C3orf18 RNA expression shows 18,787 significant gene co-expression associations, with the highest sampling consensus in UVM. Together, these results highlight KIRP, KIRC, and UVM as cancer lineages where C3orf18 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for C3orf18 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes C3orf18 survival associations across molecular data types. C3orf18 RNA expression shows survival associations in the most cancer types (24), followed by mutation status (3) and mass-spec protein abundance (1). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible C3orf18 RNA expression–survival associations across cancer types. High C3orf18 expression shows unfavorable associations in LUSC and CESC, but favorable associations in KIRP, LUAD, LGG and KIRC. The KIRP Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRP as the clearest survival context for C3orf18 RNA expression.
This table summarizes C3orf18 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 16, while mass-spec protein shows differences in 2. The strongest signals are observed in KIRC for RNA and LUAD for protein.
This table ranks reproducible tumor–normal expression differences for C3orf18. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. C3orf18 shows lower tumor expression in KIRC, THCA, BLCA, LUSC and LUAD and higher tumor expression in LIHC. The KIRC box plot shows higher C3orf18 RNA expression in normal versus tumor tissue (log2 FC = −1.040, t-test p < 0.001).
This table shows molecular features associated with C3orf18 in patient tissues and cancer cell lines. In patient samples, C3orf18 shows the broadest associations at the RNA and protein expression levels, with UVM recurring as the lineage with the largest associated feature set. In cancer cell lines, C3orf18 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in BREAST, while CRISPR and shRNA rows add functional-dependency signals in CNS and BLOOD_Lymphoma.
